How We Might Further Integrate Considerations of Environmental Impact When Assessing the Value of Health Technologies.

Canada climate change deliberative process environment guideline health care health policy health systems health technology assessment sustainability

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
22 09 2022
Historique:
received: 27 07 2022
revised: 16 09 2022
accepted: 21 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 18 10 2022
Statut: epublish

Résumé

There is growing awareness of the impact health technologies can have on the environment and the negative consequences of these environmental impacts on human health. However, health system decision-makers may lack the expertise, data, or resources to incorporate environmental considerations when making decisions about the adoption and use of health technologies. In this article, we describe how health technology assessment (HTA) is evolving to address climate change by providing health system decision-makers with the information they can use to reduce the impact of health care systems on the environment. Our objective is to consider approaches for including the environment domain when conducting an HTA-in particular, the use of the deliberative process-and for determining when the domain should be included. We explore the challenges of gathering the relevant data necessary to assess the environmental impact of a health technology, and we describe a "triage" approach for determining when an in-depth environmental impact assessment is warranted. We also summarize related initiatives from HTA agencies around the world.

Identifiants

pubmed: 36231319
pii: ijerph191912017
doi: 10.3390/ijerph191912017
pmc: PMC9566650
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Technol Assess Health Care. 2018 Jan;34(3):317-326
pubmed: 29897036
J Clin Oncol. 2022 Jun 20;40(18):1976-1979
pubmed: 35333584
Int J Technol Assess Health Care. 2020 Jun;36(3):187-190
pubmed: 32398176
Lancet. 2021 Sep 11;398(10304):939-941
pubmed: 34496267
Int J Technol Assess Health Care. 2020 Aug 04;:1-8
pubmed: 32746954
Lancet. 2009 Jul 4;374(9683):76-85
pubmed: 19577696
Cochrane Database Syst Rev. 2022 Mar 30;3:ED000156
pubmed: 35353372
PLoS Med. 2018 Jul 31;15(7):e1002623
pubmed: 30063712
BMJ Glob Health. 2019 Jan 25;4(Suppl 1):e000844
pubmed: 30775012

Auteurs

Barbara Greenwood Dufour (B)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Laura Weeks (L)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Gino De Angelis (G)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Dave K Marchand (DK)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

David Kaunelis (D)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Melissa Severn (M)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Melissa Walter (M)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Nicole Mittmann (N)

Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH